Projects funded through the Global AMR Innovation Fund (GAMRIF) will primarily benefit people in LMICs, where the burden of drug-resistant infection is greater.

The aim of this partnership is to support novel research projects that will develop the use of cutting edge solutions to tackle critical issues of AMR in humans and animals and other LMICs. This includes solutions that will: - explore opprtunities from Traditional Chinese Medicine for the treatment and/or prevention of infectious diseases in humans and animals - advance the discovery of new agents, incdluing small molecule drugs, vaccines, antibodies and other biological products - identify new agents that increase feed energy conversion in livestock without using antibiotics or hormones - use modelling and clinical studies to maxmise the clinical utility of current antibiotics - improve diagnostic capabilities for the diagnosis, treatment selection and surveillance of bacterial infections and antibacterial resistance

The UK Department of Health and Social Care (DHSC)'s UK-China research competition supports new innovations to address anti-microbial resistance (AMR) in both humans and animals, which together constitute a significant threat to human health. Successful projects are a partnership of UK companies and research organisations, with Chinese companies and research organisations. £10 million of UK aid funding has now been awarded to UK partners through delivery partner Innovate UK, with the Chinese Ministry of Science and Technology (MoST) providing funding for the Chinese partners who will receive up to a total of 60 million RMB. The output of these partnerships will benefit people in other low- and middle-income countries (LMICs) around the world.